Abstract. To investigate the effects of pirfenidone (PFD) on the attenuation of bladder remodeling, and the associated functional changes caused by partial bladder outlet obstruction (pBOO), the present study performed surgery on adult male Sprague-Dawley rats produce a model of pBOO. The rats in the pBOO group were administered a placebo and, in the CMC group, PFD mixed with the placebo was administered orally at 500 mg/kg body weight each day for 5 weeks, from 1 week after surgery. The rat bladders were harvested for biochemical analysis following cystometry at the end of the 6 week period. The histopathology was determined using Masson's trichrome staining. The mRNA and protein levels of pro-fibrotic growth factors and extracellular matrix subtypes were assessed. pBOO debilitated bladder function and caused the parameters from cystometry to increase significantly compared with those in the control group (P<0.05), which were mitigated significantly following PFD treatment (P<0.05). In terms of the histology, the rats in the pBOO group exhibited significant increases in bladder weight, muscle hypertrophy and deposition of collagens, which were suppressed by PFD treatment (P<0.05). Based on the biochemical analysis, significant increases in the mRNA levels of collagen subtypes and growth factors, and protein levels of profibrotic growth factors and α-smooth muscle actin in the bladders of rats in the pBOO group were reduced following PFD treatment. PFD prevented bladder remodeling and attenuated bladder fibrosis and, therefore, mitigated the deterioration of bladder function during the initial stage of pBOO.

Introduction

Partial bladder outlet obstruction (pBOO) is generally caused by benign prostatic hyperplasia, urethral stricture or urethral congenital malformation. Structurally and functionally, pBOO causes a series of histological and biochemical changes in the bladder wall, through a process of initial inflammation, subsequent hypertrophy and ultimately fibrosis in the decompensation stage (1). This is characterized by increased extracellular matrix (ECM) organization due to collagen synthesis, and increased expression of members of the transforming growth factor (TGF)-β family and its receptors in the stroma and epithelium (2). Particularly prevalent during the fibrotic stage of hypertrophy, bladder remodeling couples with alterations in collagen composition (3), with increased expression of type III collagen or a decreased type I/III collagen ratio (4). In addition, various cytokines, chemokines and growth factors are involved in the development of bladder fibrosis (5).

Pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone; PFD) is a small molecule pyridone compound. Since its discovery as an antifibrotic agent in a hamster model of bleomycin-induced pulmonary fibrosis (6), the use of PFD in improving organ fibrosis of the lungs (7,8), liver (9,10), kidneys (11), heart (12) and skin (13) have been investigated in vivo or in vitro. Previous studies have demonstrated PFD as a collagen and transforming growth factor (TGF)-β production inhibitor, and as an activator of matrix metalloproteinase, thus modulating the fibrogenic pathway (14). It can prevent or reverse the accumulation of extracellular matrix (ECM) by decreasing the expression of profibrotic cytokines, including tumor necrosis factor (TNF)-α and TGF-β (15).

Despite improvements in knowledge regarding the pathogenesis of pBOO-induced bladder fibrosis and the different mediators involved, there remains no effective treatment for fibrosis. The present study aimed to examine the effects of PFD on the physiological and histological markers of bladder fibrosis in a rat pBOO model. In addition, the underlying molecular mechanisms were investigated to specifically examine the mRNA and protein expression involved in ECM turnover. It was hypothesized that PFD possessed anti-fibrotic...
properties in bladder wall remodeling, resulting from pBOO in male rat model, and improve bladder function.

Materials and methods

Animals and experimental design. All the animal experiments were performed in compliance with the law, approved by the Institutional Animal Care and Use Committee of Xin Hua Hospital (Shanghai, China) (approval no. XHEC-E-2014-016). The rats were housed in a temperature-controlled room in a 12 h dark/ light cycle and had free access to water and food. PFD (cat. no. zs53179-13-8; Chembest Research, Shanghai, China) was mixed with sodium carboxymethyl cellulose (CMC; Beijing Sinopharm Chemical Reagent Co., Ltd., Beijing, China).

A total of 32 adult male Sprague-Dawley rats (Super-B&K Laboratory Animal Co., Ltd., Shanghai, China), weighing 235±10 g, were randomly divided into four groups. Group 1 ( sham-operation; n=8), served as a control, whereas in groups 2-4, surgery was performed to produce pBOO (n=24). In group 3 0.5% CMC (100 mg/kg/d) was administered via gavage, as a placebo. In group 4, PFD mixed with CMC was administered orally at 500 mg/kg body weight. Drug administration in groups 3 and 4 was performed daily for 5 weeks, beginning 1 week after surgery. The bladders of the rats were harvested for biochemical analysis following cystometry at the end of the 6 week period.

Surgical procedure for pBOO. The pBOO model was produced in the rats by ligature of the proximal urethra, as previously described (16). In brief, the rats were anesthetized with pentobarbital sodium (Huamaike Biotechnology Co., Ltd., Beijing, China) at a dose of 50 mg/kg by intraperitoneal injection. An abdominal incision of ~1.5 cm a was made, and the bilateral prostate was retracted to expose the proximal urethra. A 4-0 silk suture (Ethicon Endo-Surgery, LLC, Cincinnati, OH, USA) was placed around the urethra, and a catheter (BD Biosciences, Franklin Lakes, NJ, USA), measuring 1.10 mm in outside diameter, was placed adjacent to urethra as a calibration stent. Subsequently, the urethra and catheter were securely ligated and the catheter was carefully removed. Sham operation was performed in the same manner, without ligation of the proximal urethra.

Cystometry. The present study used a previously described cystometry method, with modifications (17). The rats were anesthetized, as mentioned above, and a 2 cm vertical abdominal incision was made, with the ligature for pBOO remaining in place. A three-way connection intravenous needle (BD Biosciences) was inserted into the bladder dome with a 6-0 polyethylene suture (Ethicon Endo-Surgery, LLC) fixation. The three-way stopcock was connected to a pressure transducer (Smiths Medical PM, Inc., Waukesha, WI, USA), which was connected to a Surgivet® Advoz® Vital Signs monitor (Smiths Medical PM, Inc.) to record the intravesical pressure. Any residual urine was collected in order to record the residual urine volume and calculate to zero. The cystometry was performed through a pump (AJ-5803; Angel Electronic Equipments Co., Ltd., Shanghai, China), to infuse room temperature saline (Baxter Healthcare Co., Ltd., Shanghai, China) at a rate of 0.2 ml/min into the bladder. Following a stabilization period of 30 min, reproducible voiding patterns were achieved and recorded for at least 90 min, due to the different voiding times in the various groups. For each rat, between six and eight voiding cycles were measured to demonstrate consistent bladder behavior. The residual urine was drained and measured following completion of the micturition cycle. The following pressure parameters were measured: Baseline pressure (BP), indicating the lowest bladder pressure during filling; threshold pressure (TP), indicating the pressure just prior to voiding; and the micturition pressure (MP), indicating the maximum pressure during urination. The volume parameters measured included the micturition volume (MV), indicating the residual urine volume and bladder capacity, which was the sum of the residual urine and micturition volumes. Additionally, the micturition interval (MI) was recorded and the bladder compliance was calculated by dividing the mean MV by the difference between the mean TP and mean BP.

Histopathology. Following cystometry, the rat bladder tissues were harvested and weighed. The rats were sacrificed by intraperitoneal injection of 10% chloral hydrate (Beijing Sinopharm Chemical Reagent Co., Ltd.), following the completion of cystometry and harvesting of the bladder tissue. Half of the harvested tissue was snap frozen in liquid nitrogen (Praxair Chemical Reagent Co., Ltd., Shanghai, China) for subsequent biochemical analysis. The other half was placed in 4% paraformaldehyde (Beijing Sinopharm Chemical Reagent Co., Ltd.) for 24 h, and was paraffin-embedded to generate 4 µm mid-bladder body transverse sections. The histopathology was examined using Masson's trichrome staining, and 10 randomly selected fields from each bladder section were analyzed using light-microscopy (DMI13000B; Leica Microsystems, Wetzlar, Germany) and a computer-assisted morphometric analyzer (LAS version 3.8.0; Leica Microsystems). The percentage of bladder tissue affected by fibrosis was determined by calculating the ratio of collagen area to smooth muscle area. Quantitative analysis of the collagen area was performed using an image analyzer system (ImageJ 1.34; National Institutes of Health, Bethesda, MA, USA).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated from the bladder tissue sections using TRIzol reagent (Takara Bio, Inc., Dalian, China). PrimeScript™ RT Master mix (cat. no. RR036A; Takara Bio, Inc.) was used to reverse transcribe RNA. Specific primers were designed from their GenBank sequences (http://www.ncbi.nlm.nih.gov/genbank/sequenceids/), synthesized by Sangon Biotech (Shanghai, China) and are listed in Table I. RT-qPCR was performed using an Applied Biosystems 7500 Fast Real Time PCR system using a SYBR® Premix Ex Taq™ kit (Takara Bio, Inc.). The PCR cycling conditions were as follows: Initial denaturation, 95°C for 30 sec; PCR, 40 cycles, 95°C for 5 sec, 60°C for 34 sec; dissociation stage, 95°C for 15 sec, 60°C for 60 sec and 95°C for 15 sec. The quantity of mRNA was calculated based on the cycle threshold (CT) values, which were standardized against the of the housekeeping gene, GAPDH. The expression levels were determined using the 2^-ΔΔCT method, with results expressed as the n-fold difference relative to the normal control.
# Immunohistochemical staining
Slides of the bladder tissues were deparaffinized using xylene (Nanjing Chemical Reagent Co., Ltd., Nanjing, China) and hydrated in graded alcohol solutions (Beijing Sinopharm Chemical Reagent Co., Ltd.). Antigen retrieval by heat mediation was performed using citrate buffer (Beyotime Institute of Biotechnology, Shanghai, China). The slides were then incubated with the primary antibodies: α-smooth muscle actin (SMA) rabbit monoclonal antibody (cat. no. 1184-1; Epitomics, Burlingame, CA, USA) diluted 1:1,000 and TGF-β1 rabbit polyclonal antibody (cat. no. sc-146; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) diluted 1:100 at 4˚C overnight. The slides were then incubated with a biotin-conjugated goat anti-rabbit immunoglobulin G (cat. no. MR-SP120; Shanghai Mingrui Biotech Co., Ltd., Shanghai, China), at room temperature. Finally, the slides were incubated with 3,3′-diaminobenzidine substrate and counterstained with hematoxylin. Control sections were incubated without the primary antibody.

## Western blot analysis
For western blot analysis, the rat bladder proteins were prepared by homogenizing in radioimmunoprecipitation assay lysis buffer fractions (Beyotime Institute of Biotechnology). Aliquots of the protein extract were transferred onto polyvinylidene fluoride membranes (EMD Millipore, Bedford, MA, USA). Following blocking in 5% skim milk (Sigma-Aldrich, St Louis, MO, USA), the membranes were incubated with the following primary antibodies overnight at 4˚C: α-SMA rabbit monoclonal antibody (1:1,000; cat. no. 1184-1; Epitomics), TGF-β1 rabbit polyclonal antibody (1:100; cat. no. sc-146; Santa Cruz Biotechnology, Inc.), rabbit polyclonal CTGF antibody (1:2,000; cat. no. ab6992; Abcam, Cambridge, MA, USA) and β-actin (1:5,000; cat. no. A3854; Sigma-Aldrich). The tris-buffered saline containing Tween-20 (Beyotime Institute of Biotechnology) washed membranes were then incubated for 1 h at room temperature with 1:2,000 secondary antibody conjugated to horseradish peroxidase (cat.no. A0208; Beyotime Institute of Biotechnology). The immunoreactive bands were visualized using enhanced chemiluminescence (EMD Millipore). Densitometric analysis of the bands was performed using Bio-Rad Image Lab™ software version 2.0 (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Negative controls were included, omitting the primary antibody. The band intensities were determined using

## Table I. Primers used for reverse transcription-quantitative polymerase chain reaction.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer (5′-3’)</th>
<th>Reverse primer (5′-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collagen-α (1) I</td>
<td>ATGTCTGGTTTGAGAGAGCA (21)</td>
<td>GAGGACGGAGCTTCTTGAG (21)</td>
</tr>
<tr>
<td>Collagen-α (1) III</td>
<td>GCCTCCCAGAACATTACATACC (22)</td>
<td>TTTGCTTTTCTCTAGCTTG (22)</td>
</tr>
<tr>
<td>Elastin</td>
<td>AGTTCGCAGGCTTTGAGCTCTATTATC (23)</td>
<td>CAAACGCTCCCCAGAAGTCC (19)</td>
</tr>
<tr>
<td>TGF-β1</td>
<td>CTGCTACCCCCACTGATAC (22)</td>
<td>CTTTATCCTCTTGCTTGTC (20)</td>
</tr>
<tr>
<td>CTGF</td>
<td>TTGTGAGGGTGGGCTGTGTATG (21)</td>
<td>AGTTGCTGGAGCAGATATGCTTG (21)</td>
</tr>
<tr>
<td>bFGF</td>
<td>GTGTCATCAAGGGAGTGTG (21)</td>
<td>CCAAAGTATGATTCTGCTTG (21)</td>
</tr>
<tr>
<td>GAPDH</td>
<td>GCAAGTCCACGGGCACAG (18)</td>
<td>GCCAGTAGACTCCAGACAT (20)</td>
</tr>
</tbody>
</table>

Numbers in brackets indicate base pairs. TGF, transforming growth factor; CTGF, connective tissue growth factor; bFGF, basic fibroblast growth factor.

---

**Figure 1.** PFD treatment inhibits the increases in bladder weight and bladder weight/body weight ratio. (A) Bladder weight, (B) body weight and (C) bladder weight/body weight ratio of rats in the sham-operation, pBOO, pBOO treated with CMC and pBOO treated with PFD groups. The obstructed rats exhibited significant increase in bladder weight. No significant difference was observed between the CMC and pBOO groups, however, PFD treatment significantly inhibited the increase in bladder weight, and in bladder weight/body weight ratio among the groups. Data are presented as the mean ± standard deviation. *P<0.05, vs. pBOO and CMC groups; **P<0.01 vs. sham group. pBOO, partial bladder outlet obstruction; CMC, carboxymethyl cellulose; PFD, pirfenidone.
densitometry and the respective intensities were corrected by β-actin.

**Statistical analysis.** Data are presented as the mean ± standard deviation. Groups of data were compared using one-way analysis of variance, followed by least significant difference multiple comparison tests. Analyses were performed using SPSS 17.0 statistical software (SPSS, Inc. Chicago, MO, USA). P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Predominant findings.** Prior to surgery, no significant differences were detected among the groups with regard to body weight. Of the total rats, two were excluded due to bladder rupture. The remaining rats were healthy at the end of the 6 week period. The mean bladder weights were 0.130±0.012, 0.640±0.141, 0.679±0.233 and 0.453±0.061 g for the sham, pBOO, CMC and PFD groups, respectively. The rats in the pBOO group exhibited significant increases in bladder weight. The bladder weights in the pBOO group were significantly increased compared with those in the sham group (P<0.01). No significant difference was found between the pBOO and CMC groups and, when the ratio of bladder:body weight was normalized, no difference was observed in the ratios between these two groups. The ratios in the pBOO and CMC groups were significantly higher compared with that the sham group (P<0.01), however, PFD treatment significantly inhibited the increase (P<0.05; Fig. 1).

**Cystometry findings.** Due to obstruction, the pressure parameters (BP, TP and MP) in the rats in pBOO and CMC groups increased compared with the sham group (P<0.05). In addition, the cystometry in the pBOO and CMC groups indicated poor bladder emptying, and increased residual urine volume and micturition interval. A significant increase in the bladder capacity was observed in the pBOO and CMC groups.
compared with the sham group (P<0.05). By contrast, TP and MP were decreased in the PFD group compared with the pBOO and CMC groups (P<0.05), and a significant decrease in the residual volume and bladder capacity were observed in the PFD group compared with these two groups (P<0.05), however, PFD treatment did not change the BP, MV, MI or bladder compliance significantly (Table II).

**Histopathology.** Following Masson’s trichrome staining, the collagen was stained blue and muscle was counterstained red.
The bladder samples in the pBOO groups revealed smooth muscle hypertrophy and fibrotic lesions compared with the sham group (Fig. 2A-C). The rats in the pBOO and CMC groups exhibited a similar muscle thickness and collagen distribution. pBOO caused hypertrophy of the detrusor muscle and increased the deposition of collagen fibers in the regions of the lamina propria and interfascicular area of the bladder musculature, compared with the sham-operated group. Treatment with PFD treatment following pBOO bladder did not normalize smooth muscle hypertrophy, however, the collagen content was markedly decreased in the lamina propria and interfascicular area (Fig. 2D). Since collagen deposition was observed in the pBOO and CMC groups, the ratio of collagen to smooth muscle was increased, however, PFD treatment inhibited the increase significantly (P<0.05; Fig. 2E).

RT-PCR. Collagen-α (1) I, collagen-α (1) III and elastin were significantly upregulated in the pBOO groups compared with the sham-operated group. Comparison between the groups with regard to PFD treatment revealed a significant difference, with the PFD group exhibiting reduced amplification of collagen-α (1) I, collagen-α (1) III and elastin compared with the pBOO and CMC groups (Fig. 3A). Compared with the sham-operated group, analysis of the gene expression of TGF-β1 confirmed no statistically significant increase in the pBOO and CMC groups (P>0.05), however, there was a 2.5-fold increase in the mRNA expression of CTGF and a 2.9-fold increase in the mRNA expression of bFGF in the pBOO group. Among the operated groups, the amplification of CTGF was significantly lower in the PFD group (P<0.01). On analyzing the effect of PFD, the gene expression of bFGF in the PFD group was lower compared with the pBOO and CMC groups (P<0.01), whilst no significant difference in expression was observed between the pBOO and CMC groups (Fig. 3B).

Immunohistochemical staining and western blot analysis. TGF-β1 was detected in the round cells of the bladder endothelium (Fig. 4A1-D1) and α-SMA was detected in the bladder lamina propria and smooth muscle cells of the rats in the pBOO group. Hypertrophic smooth muscle cells exhibited increased expression of α-SMA compared with those in the sham-operated group, as assessed by immunohistochemistry.
Discussion

The present study constructed a pBOO model in rats through surgical ligation. The effects on function and bladder remodeling of pBOO were then analyzed using cystometry and histopathology, respectively. The gene expression levels of pro-fibrotic growth factors and collagen subtypes were examined in rat bladder tissues in which detrusor muscle hypertrophy was induced via pBOO. Additionally, the protein expression levels and distributions were determined using immunohistochemistry and western blot analysis. The effect of PFD in the pBOO model was also examined. The results demonstrated that PFD reduced the gene expression of pro-fibrotic growth factors and collagen subtypes. These results were in accordance with previous studies reporting anti-fibrotic properties of PFD (13,18).

Due to obstruction, bladder wall remodeling, comprising extensive hypertrophy and increased ECM deposition, occur, all of which cause significant alteration in bladder function. The hypertrophy of bladder smooth muscle cells (BSMCs) and alteration in the architectural organization of collagen in response to pBOO result in altered BSMCs/ECM interactions, which causes a loss of BSMC contractility (19). In the PFD-treated rats, which had received pBOO, the collagen content was markedly decreased in the lamina propria and interfascicular area, however, the hypertrophy of the BSMCs was not normalized by PFD treatment. The composition of ECM is important in maintaining bladder function. Collagen and elastin are the predominant components of ECM, and an increase in their ratios may result in stiffness of the bladder wall and reduced compliance of the bladder (20-22). In the present study, 6 weeks following pBOO, pathological investigations revealed extensive hypertrophy of the BSMCs and deposition of collagen, leading to an increase in bladder weight. In addition, biochemical analysis demonstrated different elevated gene expression levels of collagen subtypes and elastin. As collagen deposition was dominant, the ratio of collagen/smooth muscle was found to be increased compared with that in the normal bladder. Notably, the present study demonstrated that bladder compliance at the end of the 6 weeks in the pBOO group was increased. A possible explanation for this observation was that the initial increases in the elastin/collagen ratio resulted from the upregulation of elastin production, which was closely paralleled with bladder mechanical compliance. Previous studies have revealed that, in a rat model of spinal cord injury, bladder compliance was increased 3 weeks and 6 weeks after injury, which was closely associated with the collagen/elastin ratio (23). In the present study, bladder compliance was increased 6 weeks after pBOO, on which PFD had no significant effect.

The nature of urinary BSMCs is to remain in a contractile, non-proliferative state, characterized by the expression of h-caldesmon and α-SMA. However, urinary BSMCs can become synthetic in response to pathological stimuli. Hypertrophic BSMCs express increased levels of α-SMA compared with normal cells (24). In the present study, paraffin sections were immunostained for α-SMA, a marker for myofibroblasts and smooth muscle cells. Compared with the sham-operated bladder tissues, the phenotypic changes in the BSMCs of the pBOO tissues caused a significant increase in the synthesis of α-SMA, which suggested a shift to a myofibroblast phenotype, similar to that of fibroblasts in healing wounds and of smooth muscle cells in the cardiovascular system (25). In the PFD-treated pBOO group, α-SMA synthesis in the BSMCs was decreased, which was not simply recognized as a direct inhibition of PFD. Since TGF-β signaling is reported to be involved in smooth muscle differentiation, it is important to determine the cellular composition of stromal expansion (19).

TGF-β1 is a 25 kDa homodimer and heterodimer, present in a wide variety of tissues, which interacts with specific cell membrane receptors and serves as a characterized mediator of cellular phenotype in fibrotic diseases (26,27). In BSMCs TGF-β1 induces hypertrophy and the upregulation of collagen (28), and inhibits proliferation (29). In the present study, the hypertrophied rat bladders, produced following urethral constriction exhibited increased urothelial expression of TGF-β1, hypertrophy of smooth muscle, and increased expression of type III collagen. This suggested that the TGF-β1 from the urothelium acted as a paracrine signal, stimulating the proliferation and matrix production of the BSMCs, thereby contributing to the hypertrophic remodeling of the smooth muscle layer, which was inhibited by PFD treatment. Biologically active TGF-β requires dimerization of its monomers and the releases of its latent peptide portion. In the present study PFD was observed to inhibit the increased protein levels of biologically active TGF-β caused by pBOO. An important aspect of the antifibrotic mechanism of PFD is associated with its inhibition of the production and activity of TGF-β (30).

In addition to antifibrotic properties, the antioxidant (31) and anti-inflammatory activities of PFD have been documented (32), and, although significant attention has been focused on the antifibrotic effect of the drug, the precise mechanism remains to be elucidated. In an animal model of hepatic fibrosis, PFD decreases the mRNA expression levels of TGF-β and collagen type 1 (33). Additionally, PFD serves as a novel regulator of the gene expression of cytokines and has the potential to ameliorate established radiation-induced fibrosis (34). A previous study investigating the effects of PFD on secondary progressive multiple sclerosis found that PFD treatment for 20 months not only inhibited the progression of multiple sclerosis, but also significantly improved bladder function (35). PFD has entered the clinical phase of investigation in various fibrotic diseases and the range of doses used fluctuate between 1,800 and 3,600 mg/day. In the present study, a PFD dose of 500 mg/kg/day, which is a large dose in humans, was used, based on a preliminary experiment that 200 mg/kg/day of PFD had no significant effects (data not shown) and from previous genotoxic evaluation of...
PFD using an erythrocyte rodent micronucleus assay (36). In addition, due to focusing predominantly on the effect of PFD on the fibrosis-associated mRNA and protein expression of growth factors, the detailed signaling pathway was not further examined. The mechanism of PFD is through its downregulation of a series of cytokines, including TGF-β1, CTGF and TNF-α (30). In the present study, no significant difference was observed between the mRNA levels of TGF-β1 in the bladder tissues of the pBOO rats compared with the sham-operated rats. Increases in the mRNA expression levels of CTGF and bFGF were observed, however, these levels were significantly reduced by PFD, which suggested that PFD inhibited the progression of bladder function via its anti-fibrotic action.

In the present study, an experimental animal model for obstruction of the bladder neck, induced by ligation, was used. Following construction of the obstruction model, physical examination was performed each day to assure the formation of obstruction and analysis using cystometry was performed while the animals were anesthetized. Urodynamic investigations using pentobarbital sodium may not be optimal, however, the initial objective of the present study was to collect data on bladder pressure, bladder capacity and compliance. In addition, continuous cystometry can be reproducibly performed in anesthetized, non-obstructed rats and in rats with pBOO (37).

In conclusion, the results of the present study support the hypothesis that pirfenidone exhibits anti-fibrosis properties in bladder tissue. These results may provide a future avenue for treatment of bladder fibrosis.

Acknowledgements

This study was sponsored by the Natural National Science Foundation of China (no. 81070600) and the Foundation of Shanghai Science and Technology Committee (grant nos. 134119a0600 and 14430720800).

References